RUNX1 and Alzheimer disease: Furthermore, the regulatory effect of RUNX1 on SLC22A4 and the activation effect of ROS on p53 may suggest that EGT is transported to clear excess ROS through the high expression of OCTN-1 or that the anti-inflammatory effect of inhibiting IL-33 alleviates AD after the skin barrier function is impaired.